Australia, September 2025 – Costa Saroukos has been appointed as the Chairman of the Board at Mitsubishi Tanabe Pharma, marking a new chapter in his illustrious global career in finance and pharmaceuticals. Based remotely from Australia, Saroukos is set to bring decades of strategic leadership, financial acumen, and board-level governance to the company’s global operations and long-term vision.
Prior to this appointment, Costa Saroukos spent over a decade at Takeda, holding multiple key roles, including Chief Financial Officer for nearly six years, and Board Member for over seven years, based in Tokyo. He also served as Vice President CFO for Europe & Canada, and briefly as Interim President and CFO for the region, where he oversaw major financial operations and strategic planning across multiple markets.
Before joining Takeda, he held senior roles at Allergan in Asia, including Vice President Finance Asia Pacific and Regional CFO for Greater China & Japan. His leadership at Allergan saw him managing finance for a broad and complex region, including China, Japan, Taiwan, and Hong Kong, with a focus on operational efficiency and strategic growth.
Saroukos also spent more than 13 years with Merck, where he took on increasingly senior roles across geographies—from Executive Director Finance for Eastern Europe, Middle East & Africa, to Regional Finance Director for Africa, and Finance & Business Development Director for South Korea. His journey at Merck began as a Corporate Audit Manager and Financial Planning & Tax Manager in Australia, building a strong foundation in compliance, M&A, and financial transformation.
This extensive global exposure across Japan, Switzerland, Korea, Singapore, and Australia, combined with board-level insights, makes Saroukos a uniquely qualified leader to guide Mitsubishi Tanabe Pharma through its next phase of growth and innovation.
About Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma Corporation is a leading Japanese pharmaceutical company headquartered in Osaka and is a subsidiary of Mitsubishi Chemical Holdings Corporation. Formed through the merger of Mitsubishi-Tokyo Pharmaceuticals and Welfide Corporation in 2001, and later merged with Tanabe Seiyaku Co., Ltd. in 2007, the company has a rich legacy in medical innovation. Mitsubishi Tanabe Pharma is committed to developing life-changing therapies and operates with a focus on neurological, immunological, and rare diseases. Its global reach, combined with deep Japanese heritage, places it at the forefront of advancing healthcare solutions for complex medical needs.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
